A few factors to consider:
1. The stock has been on a tear in 2014, up 35%. Time for a breather.
2. Not getting the sales numbers. Down 18% year-over-year.
3. New shares issued.
4. Huge charge in Q3, ramps up loss per share to $6, from $1.3 last year.
I can't see any other publicly traded options to offset this position. So it is not part of an obvious strategy. Unlikely as it seems, it could just be some buyer with $210k to spare, and a rich shareholder comfortable with making a quick $210k on his $2 million stash. In a few weeks, somebody will be proved wrong. In practice, it's the option buyer who does the crying, 90% of the time.
I say their business is bad because they lose money. And it does not take much "research" to find that out: STXS is publicly traded, and their P&L statements are one click away. Any money they manage to make in sales, they match and then some in expenses. Every year, every quarter. As for manipulation,I have never, I say again never, witnessed a pump & dump such as that experienced by STXS stock last summer. 5X price rise, 25X daily volume increase, entire retail float traded before lunchtime. Madness. By the way, the stock tanked the following 2 weeks, price down by two-thirds.
This is a microcap stock, vulnerable to attacks from speculators. "Risk capital" is all that a retail investor should prudently commit to this stock. Consider it a gamble, an entertainment. Buy 100 shares; if it really does get back to 10, enjoy a dinner for 2 at a nice restaurant on your winnings. With the rest of your nest egg, buy a Vanguard biotech fund and sleep well.
The future price of STXS? Who knows? There are a thousand companies like Stereotaxis: good technology, bad business. Their management's stories are always the same: new markets, government approval, potential buyouts. In the future. Always the future. "Forward-looking statements" they are called. Because in the here and now, they are losing money. But with the next round of (equity-diluting) financing, they can make it to the next crisis point. Lather and repeat.
As for the stock., the story of manipulation is clear. July 2013 low $1.10; August 2013 high $9.90. It went from 2 to 10 (intraday) in one week! Obviously, nothing fundamentally changed in the interim. But a few folks got rich.
Careful with this stock. Retail investors are severely disadvantaged.
Sure looks like some traders are looking for a price increase in the next 5 weeks. And for us retail longs, an ICPT-like experience would be oh-so-sweet. OTOH, options trading is neatly balanced between longs and shorts. For instance, re the Feb 8 calls, some wealthy shareholder just made himself a quick $700k. Who's to say he made a dumb move? Time will tell of course, but is this 7.44 stock really going to be over 9 dollars next month?
No shame in an individual stock not following the average trend. That's why people invest in individual issues: to escape the average trend line--of course hoping to better the trend.
If you see the trend as your friend, take a look at IBB, Ishares Biotech ETF. It was up a smart 2.8% yesterday, and a comfy 60% for the calendar year. Maybe you would sleep better owning IBB. EXEL has certainly been a heartbreaker.